These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27183094)

  • 61. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry.
    Courant M; Orazio S; Monnereau A; Preterre J; Combe C; Rigothier C
    Nephrol Dial Transplant; 2021 Feb; 36(3):482-490. PubMed ID: 31773154
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.
    Akı SZ; Pamukçuoğlu M; Bağrıaçık Ü; Sucak GT
    Leuk Lymphoma; 2013 Apr; 54(4):894-6. PubMed ID: 23039261
    [No Abstract]   [Full Text] [Related]  

  • 63. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
    Alberts DS; Chen HG; Benz D; Mason NL
    Br J Cancer; 1981 Mar; 43(3):330-4. PubMed ID: 7225283
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Clinical characteristics of multiple myeloma with renal impairment and the efficacy of different treatments].
    Liu Y; Ke X; Wang J; Wang Y; Wan W; Zhang W
    Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):842-4. PubMed ID: 25246256
    [No Abstract]   [Full Text] [Related]  

  • 65. Re: Toxicity of intrathecal melphalan.
    Friedman HS; Archer G; Bigner DD
    J Natl Cancer Inst; 1994 Jun; 86(11):870-1. PubMed ID: 8043096
    [No Abstract]   [Full Text] [Related]  

  • 66. Re: Toxicity of intrathecal melphalan.
    Berg S; Balis FM; McCully CL; Poplack DC
    J Natl Cancer Inst; 1994 Mar; 86(6):463. PubMed ID: 8120922
    [No Abstract]   [Full Text] [Related]  

  • 67. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation.
    Merz M; Jansen L; Castro FA; Hillengass J; Salwender H; Weisel K; Scheid C; Luttmann S; Emrich K; Holleczek B; Katalinic A; Nennecke A; Straka C; Langer C; Engelhardt M; Einsele H; Kröger N; Beelen D; Dreger P; Brenner H; Goldschmidt H;
    Eur J Cancer; 2016 Jul; 62():1-8. PubMed ID: 27185572
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
    El-Ghammaz AM; Abdelwahed E
    Ann Hematol; 2016 Aug; 95(8):1315-21. PubMed ID: 27184486
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.
    Brown S; Hinsley S; Ballesteros M; Bourne S; McGarry P; Sherratt D; Flanagan L; Gregory W; Cavenagh J; Owen R; Williams C; Kaiser M; Low E; Yong K;
    BMC Hematol; 2016; 16():14. PubMed ID: 27190631
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.
    Majithia N; Rajkumar SV; Lacy MQ; Buadi FK; Dispenzieri A; Gertz MA; Hayman SR; Dingli D; Kapoor P; Hwa L; Lust JA; Russell SJ; Go RS; Kyle RA; Kumar SK
    Leukemia; 2016 Nov; 30(11):2208-2213. PubMed ID: 27211270
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Xiu L; Cakana A; Parekh T; San-Miguel JF
    Cancer; 2016 Jul; 122(13):2050-6. PubMed ID: 27191689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
    Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
    Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
    Usmani SZ; Weiss BM; Plesner T; Bahlis NJ; Belch A; Lonial S; Lokhorst HM; Voorhees PM; Richardson PG; Chari A; Sasser AK; Axel A; Feng H; Uhlar CM; Wang J; Khan I; Ahmadi T; Nahi H
    Blood; 2016 Jul; 128(1):37-44. PubMed ID: 27216216
    [TBL] [Abstract][Full Text] [Related]  

  • 74. NCCN Guidelines Update for Multiple Myeloma.
    Anderson KC
    J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):675-7. PubMed ID: 27226512
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
    Gupta N; Hanley MJ; Harvey RD; Badros A; Lipe B; Kukreti V; Berdeja J; Yang H; Hui AM; Qian M; Zhang X; Venkatakrishnan K; Chari A
    Br J Haematol; 2016 Sep; 174(5):748-59. PubMed ID: 27196567
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel Combination Treatments in Multiple Myeloma.
    Nooka AK; Lonial S
    Oncology (Williston Park); 2016 May; 30(5):451-65. PubMed ID: 27188677
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Emerging antibodies for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
    Chalayer E; Chapelle C; Leleu X; Elalamy I; Laporte S; Tardy B
    Thromb Res; 2016 Jul; 143():101-2. PubMed ID: 27208979
    [No Abstract]   [Full Text] [Related]  

  • 79. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
    Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
    Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New Drugs Prompt Myeloma Guidelines Update.
    Cancer Discov; 2016 Jul; 6(7):684. PubMed ID: 27207892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.